SEC Form 4 · accession 0001209191-18-043367
INTEGRA LIFESCIENCES HOLDINGS CORP · IART
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart Essig
Director
Period of report
Jul 17, 2018
Accepted (ET)
Jul 19, 2018 · 5:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000917520
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 17, 2018 | M | 31,353 | $21.12 | A | 1,450,272 | D | |
| Common StockF2 | Jul 17, 2018 | S | 31,353 | $63.5021 | D | 1,418,919 | D | |
| Common Stock | holding | — | — | — | 608,700 | I | By GRAT |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F3 | $21.12 | Jul 17, 2018 | M | 31,353 | D | — | Aug 14, 2018 | Common Stock | 31,353 | 69,871 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
- F2The price shown above represents the weighted average price of the shares sold. The range of sale prices was $63.50 to $63.57.
- F325% of the option grant vested on 8/14/2009 (the first anniversary of the grant date of 8/14/2008), and the remaining 75% vested monthly thereafter over 36 months.